Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 10;383(11):1083-1085.
doi: 10.1056/NEJMc2000069.

Racial Differences in Genomic Profiling of Prostate Cancer

Brandon A Mahal  1 , Mohammed Alshalalfa  2 , Kevin H Kensler  2 , Ilkania Chowdhury-Paulino  3 , Philip Kantoff  4 , Lorelei A Mucci  3 , Edward M Schaeffer  5 , Daniel Spratt  6 , Kosj Yamoah  7 , Paul L Nguyen  2 , Timothy R Rebbeck  2
Affiliations

Racial Differences in Genomic Profiling of Prostate Cancer

Brandon A Mahal et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Tumor-Mutation Profiles in the 2393 Study Patients.
Shown are tumor-mutation profiles according to race among men with primary prostate cancer (Panels A, C, and E) or metastatic prostate cancer (Panels B, D, and F). The data were obtained from targeted tumor-sequencing testing available to patients at the Memorial Sloan Kettering (MSK) Cancer Center (Integrated Mutation Profiling of Actionable Cancer Targets [IMPACT]) and from the Dana–Farber Cancer Institute (Oncopanel next-generation sequencing). (Details regarding testing methods are provided in the Supplementary Appendix.) Among the 2393 patients who were included in the study, 1484 patients had primary tumors, and 909 patients had metastatic tumors. The total mutation count in the two subgroups (Panels A and B) was calculated in the MSK-468 cohort (the largest subgroup in the study), in which patients were evaluated on a next-generation sequencing panel of 468 unique genes. Mutational frequency is shown for the genes that were most commonly altered in the study (Panels C and D). Actionable mutations are alterations that are the intended targets of precision-oncology drugs. Genes with actionable mutations (Panels E and F) include ABL1, EGFR, ERBB2, BRAF, BRCA1/2, FGFR2/3, KIT, NTRK1/2/3, PDGFRA, RET, ROS1, ALK, and PIK3CA. Among the patients with metastatic prostate cancer, genes with actionable mutations occurred more often in Black men than in White men (26.7% vs. 18.0%, P=0.05). DNA-repair genes include ERCC5, MRE11, TP53BP1, POLE, RAD21, MSH2, MSH6, BRCA1/2, ATR, and ATM. Mutations in DNA-repair genes occurred more often in Black men than in White men (22.5% vs. 15.6%, P=0.05) among those with metastatic disease.
See this image and copyright information in PMC

References

    1. Dess RT, Hartman HE, Mahal BA, et al. Association of black race with prostate cancer-specific and other-cause mortality. JAMA Oncol 2019;5:975–83. - PMC - PubMed
    1. Mahal BA, Alshalalfa M, Spratt DE, et al. Prostate cancer genomic-risk differences between African-American and white men across Gleason scores. Eur Urol 2019;75:1038–40. - PubMed
    1. Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. Clinical use of current polygenic risk scores may exacerbate health disparities. Nat Genet 2019;51:584–91. - PMC - PubMed
    1. AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discov 2017;7:818–31. - PMC - PubMed
    1. Spratt DE, Osborne JR. Disparities in castration-resistant prostate cancer trials. J Clin Oncol 2015;33:1101–3. - PMC - PubMed